Health Care • Biotechnology: Pharmaceutical Preparations
$21.10 ▲ +0.72
(+3.53%)
MKT CAP: $1.13B • VOL: 272.2K
52W L $15 52W H $28
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$18
MEDIAN
$24
MEAN
$24
HIGH
$29
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE SPTX TAPE
SPTX // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $25.53 | $24.27 | 2025-02-14 | $19.20 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $26.59 | $24.90 | 2025-02-06 | $19.83 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $24.05 | $23.21 | 2025-01-29 | $20.26 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $21.52 | — | 2025-01-17 | $20.68 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $18.57 | $20.05 | 2025-01-09 | $18.78 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $25.11 | $21.94 | 2024-12-18 | $18.36 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $20.47 | $21.31 | 2024-12-04 | $19.62 | -4.3% | 48% | C |